Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia.

Marshall LE, Nelson M, Davies CH, Whelan AO, Jenner DC, Moule MG, Denman C, Cuccui J, Atkins TP, Wren BW, Prior JL.

J Immunol Res. 2018 Nov 29;2018:8087916. doi: 10.1155/2018/8087916. eCollection 2018.

2.

Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.

Cuccui J, Thomas RM, Moule MG, D'Elia RV, Laws TR, Mills DC, Williamson D, Atkins TP, Prior JL, Wren BW.

Open Biol. 2013 May 22;3(5):130002. doi: 10.1098/rsob.130002.

3.

Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies to Francisella tularensis.

Stefanetti G, Okan N, Fink A, Gardner E, Kasper DL.

Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7062-7070. doi: 10.1073/pnas.1900144116. Epub 2019 Mar 14.

4.

Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies.

Chen L, Valentine JL, Huang CJ, Endicott CE, Moeller TD, Rasmussen JA, Fletcher JR, Boll JM, Rosenthal JA, Dobruchowska J, Wang Z, Heiss C, Azadi P, Putnam D, Trent MS, Jones BD, DeLisa MP.

Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):E3609-18. doi: 10.1073/pnas.1518311113. Epub 2016 Jun 6.

5.

Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Richard K, Mann BJ, Stocker L, Barry EM, Qin A, Cole LE, Hurley MT, Ernst RK, Michalek SM, Stein DC, Deshong P, Vogel SN.

Clin Vaccine Immunol. 2014 Feb;21(2):212-26. doi: 10.1128/CVI.00738-13. Epub 2013 Dec 18.

6.

Characterization of Inner and Outer Membrane Proteins from Francisella tularensis Strains LVS and Schu S4 and Identification of Potential Subunit Vaccine Candidates.

Post DMB, Slütter B, Schilling B, Chande AT, Rasmussen JA, Jones BD, D'Souza AK, Reinders LM, Harty JT, Gibson BW, Apicella MA.

MBio. 2017 Oct 10;8(5). pii: e01592-17. doi: 10.1128/mBio.01592-17.

7.

Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Richard K, Mann BJ, Qin A, Barry EM, Ernst RK, Vogel SN.

Clin Vaccine Immunol. 2017 Mar 6;24(3). pii: e00574-16. doi: 10.1128/CVI.00574-16. Print 2017 Mar.

8.

Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains.

Wu TH, Zsemlye JL, Statom GL, Hutt JA, Schrader RM, Scrymgeour AA, Lyons CR.

Vaccine. 2009 Jul 23;27(34):4684-93. doi: 10.1016/j.vaccine.2009.05.060. Epub 2009 Jun 9.

9.

A ΔclpB mutant of Francisella tularensis subspecies holarctica strain, FSC200, is a more effective live vaccine than F. tularensis LVS in a mouse respiratory challenge model of tularemia.

Golovliov I, Twine SM, Shen H, Sjostedt A, Conlan W.

PLoS One. 2013 Nov 13;8(11):e78671. doi: 10.1371/journal.pone.0078671. eCollection 2013.

10.

Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles.

Whelan AO, Flick-Smith HC, Homan J, Shen ZT, Carpenter Z, Khoshkenar P, Abraham A, Walker NJ, Levitz SM, Ostroff GR, Oyston PCF.

PLoS One. 2018 Oct 8;13(10):e0200213. doi: 10.1371/journal.pone.0200213. eCollection 2018.

11.

Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.

Tian D, Uda A, Park ES, Hotta A, Fujita O, Yamada A, Hirayama K, Hotta K, Koyama Y, Azaki M, Morikawa S.

Microbiol Immunol. 2018 Jan;62(1):24-33. doi: 10.1111/1348-0421.12555. Epub 2018 Jan 1.

PMID:
29171073
12.

Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates.

Chu P, Cunningham AL, Yu JJ, Nguyen JQ, Barker JR, Lyons CR, Wilder J, Valderas M, Sherwood RL, Arulanandam BP, Klose KE.

PLoS Pathog. 2014 Oct 23;10(10):e1004439. doi: 10.1371/journal.ppat.1004439. eCollection 2014 Oct.

13.

Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.

Hickey AJ, Hazlett KR, Kirimanjeswara GS, Metzger DW.

Vaccine. 2011 Sep 16;29(40):6941-7. doi: 10.1016/j.vaccine.2011.07.075. Epub 2011 Jul 29.

14.

Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A.

Wu TH, Hutt JA, Garrison KA, Berliba LS, Zhou Y, Lyons CR.

Infect Immun. 2005 May;73(5):2644-54.

15.
17.

Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.

Reed DS, Smith LP, Cole KS, Santiago AE, Mann BJ, Barry EM.

Infect Immun. 2014 May;82(5):2098-105. doi: 10.1128/IAI.01498-14. Epub 2014 Mar 10.

18.

Protective immunity against tularemia provided by an adenovirus-vectored vaccine expressing Tul4 of Francisella tularensis.

Kaur R, Chen S, Arévalo MT, Xu Q, Chen Y, Zeng M.

Clin Vaccine Immunol. 2012 Mar;19(3):359-64. doi: 10.1128/CVI.05384-11. Epub 2012 Jan 25.

19.
20.

Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.

Conlan JW, Shen H, Golovliov I, Zingmark C, Oyston PC, Chen W, House RV, Sjöstedt A.

Vaccine. 2010 Feb 17;28(7):1824-31. doi: 10.1016/j.vaccine.2009.12.001. Epub 2009 Dec 16.

Supplemental Content

Support Center